Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Omar Alsharif

Hospitalist Knoxville, TN Medical Doctor

NPI 1548758527 CMS profile 8807465

1924 Alcoa Hwy # U56, Knoxville, TN 37920

Open in the dashboard

General payments

$5,645

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Omar Alsharif of Knoxville, TN is reported in the CMS Open Payments database as having received $5,645 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,555 109
2024 General $2,163 88
2023 General $696 36
2022 General $112 6
2021 General $31 2
2020 General $71 5
2019 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Omar Alsharif
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Omar Alsharif were reported at $2,555. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Omar Alsharif Hospitalist median Middle half National median
2019 $17 $96 $28–$201 $163
2020 $71 $48 $19–$125 $114
2021 $31 $70 $23–$167 $132
2022 $112 $85 $27–$174 $149
2023 $696 $89 $30–$191 $160
2024 $2,163 $95 $29–$204 $164
2025 $2,555 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $546 11 payments
  2. Merck Sharp & Dohme Corporation $404 17 payments
  3. Janssen Biotech, Inc. $363 18 payments
  4. E.R. Squibb & Sons, L.L.C. $318 24 payments
  5. Novartis Pharmaceuticals Corporation $311 13 payments
  6. Incyte Corporation $280 11 payments
  7. Pfizer Inc. $265 10 payments
  8. Genentech USA, Inc. $214 11 payments
  9. AbbVie, Inc. $206 4 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $174 8 payments
  11. Other $2,563 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,913 239 payments
  2. Education $732 8 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $380 16 payments
  2. OPDIVO $282 21 payments
  3. VENCLEXTA $206 4 payments
  4. KISQALI $165 7 payments
  5. FOTIVDA $158 5 payments
  6. LIBTAYO $154 6 payments
  7. NINLARO $127 6 payments
  8. RYBREVANT $120 6 payments
  9. REBLOZYL $120 6 payments
  10. LYNPARZA $111 5 payments
  11. Other $4,422 220 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Hospitalist: 109

Drug cost

$265

Median for Hospitalist: $6,399

Branded share of claims

0%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Letrozole Generic 11 $265

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 57 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VENCLEXTA
  • AbbVie, Inc. $206
  • Genentech USA, Inc. $39
$245 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $179
$179 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $89
$89 — —
RYBREVANT
  • Janssen Biotech, Inc. $81
$81 — —
TECVAYLI
  • Janssen Biotech, Inc. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 57 with Patron

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record